Persistent pulmonary hypertension of the newborn (PPHN) is an abnormal early adaptation to the perinatal circulation transition. Failure of the normal postnatal decline in pulmonary vascular resistance (PVR) leads to right-to-left intra-or extra-cardiac shunting, (which impairs systemic oxygenation) and right ventricular failure. PPHN affects 2 to 6 per 1000 live births (1) . Mortality rate is still high (up to 48%) and adverse neurological sequelae in survivors are common (up to 46%) (2) .
In the pre inhaled nitric oxide (iNO) era (before 1993), a wide variation in treatment of this entity was noted and one of the possibilities was the use of neuromuscular blockers (3, 4) . We present a patient with PPHN refractory to iNO for whom neuromuscular blockers were beneficial.
We report the case of a male infant who was delivered by emergency caesarean section at 27 weeks of gestation because of placental abruption. The patient was born in a regional hospital, but was nonetheless taken (Fig. 3) . In the following 48 hours, iNO was weaned and the patient was successfully extubated on day 5 of life. Due to positive blood cultures for Staphylococcus aureus, amoxicillin and gentamycin were discontinued after 4 days and replaced by vancomycin; this treatment was continued for 2 weeks. Secondly, the neuromuscular blocker could have triggered the release of histamine, which has been described to act as a pulmonary vasodilator in two studies in dogs and rats (9, 10); however, our patient did not present any signs of systemic vasodilatation. Thirdly, respiratory paralysis may have reduced oxygen consumption and peak transthoracic pressures, but our patient was ventilated on HFOV and was already apneic prior to curare. Finally, thoracic rigidity caused by fentanyl is possible but would not be expected to significantly impair ventilation on HFOV; however, by paralysing the diaphragm and the abdominal wall muscles, the intra-abdominal pressure might have decreased, possibly decreasing the intra-thoracic pressure, improving lung recruitment, decreasing PVR and hence right-to-left shunting.
Fig. 3

Evolution of the pre-and post-ductal saturations (dashed blue and full green line, respectively) as well as lactate concentrations (squares, secondary scale on the right) in relation to different interventions (vertical arrows).
In conclusion, since iNO has been introduced to treat PPHN, neuromuscular blocking agents are only rarely used. Nevertheless, they might still be useful in some selected newborns with PPHN refractory to classical treatments.
